Accelerating Medicines Partnership—Diabetes
At a Glance
- Status: Active Consortium
- Year Launched: 2014
- Initiating Organization: Foundation for the National Institutes of Health
- Initiator Type: Nonprofit foundation
- Disease focus:
Type 2 Diabetes
- Location: North America
The Accelerating Medicines Partnership (AMP) is a consortium of the National Institutes of Health (NIH), 10 biopharmaceutical companies, and several nonprofit organizations. The AMP diabetes project focuses on identifying genetic biomarkers that are correlated to Type 2 diabetes (T2D), with particular emphasis on accelerating development of novel drugs for this disease.
AMP brings together government, industry, and nonprofit organizations to identify and validate the most promising biological targets of disease for new diagnostic and drug development. Although therapies for T2D are available, none can reverse disease progression or prevent disease complications. The approach of the AMP diabetes project is to use and supplement a large amount of recently generated genetic data on T2D in diverse populations to validate novel molecules and pathways as targets for therapeutic development.
The AMP diabetes project began in mid-2014 and will be a five-year initiative.
Structure & Governance
The AMP diabetes project is managed by a Steering Committee consisting of representatives from NIH, the Foundation for the NIH (FNIH), participating companies, and patient advocacy organizations. After AMP research grant awards are made, investigators are added to the Steering Committee. The Steering Committee is responsible for defining the research agenda and project plan, reviewing ongoing projects, and assessing milestones. The Steering Committee operates under the direction of the overall AMP Executive Committee consisting of representatives from the NIH, FNIH, participating companies, the Food and Drug Administration, and patient advocacy organizations.
The AMP diabetes project will receive $58.4 million in total funding, with $30.4 million from the NIH and $28 million from industry partners.
AMP is designed to be precompetitive and will neither make use of preexisting intellectual property nor produce patentable findings.
AMP initiative will deposit all data in a repository that will be accessible for use by the biomedical community and all qualified investigators, consistent with applicable laws, regulations, and policies, and unencumbered by any intellectual property claims.
Over the five-year project, researchers will build a database of DNA sequence, functional genomic, and epigenomic information and clinical data from studies of T2D and its cardiac and renal complications. The database will include data from 100,000 to 150,000 individuals combined into a T2D knowledge portal accessible to academic and industry researchers to identify and validate changes in DNA that spur the onset of diabetes, alter disease severity, speed or slow down disease progression, or have a protective effect. In addition, new genomic data that fill gaps in the knowledge portal will be generated by executing specific analysis, including DNA sequencing of particular individuals.
Points of Contact
Sanya Fanous Whitaker, PhD, PMP
Scientific Project Manager
Sponsors & Partners
American Diabetes Association
Foundation for the NIH
Johnson & Johnson
Juvenile Diabetes Research Foundation (JDRF)
National Institutes of Health